PTK7 Signaling in Cancer Development and Progression

Protein tyrosine kinase 7 (PTK7) is a catalytically inactive receptor tyrosine pseudokinase that is aberrantly expressed across a spectrum of malignancies. Although lacking enzymatic activity, PTK7 exerts profound effects on tumour cell behaviour by acting as a modulator of key signalling networks. Through heterodimerisation with active receptor tyrosine kinases, PTK7 influences downstream effectors such as the Wnt/β-catenin pathway, MAPK cascades and PI3K/Akt signalling. These interactions promote cellular processes central to oncogenesis, including proliferation, migration, invasion and evasion of apoptosis. Proteolytic cleavage of PTK7 generates distinct fragments that translocate to the nucleus or remain membrane-bound, further diversifying its signalling repertoire. Elevated PTK7 expression has been linked with poor prognosis, metastatic spread and resistance to conventional therapies in tumours such as breast, ovarian and gastrointestinal cancers. Recent advances have illuminated PTK7’s role in the tumour microenvironment, where it modulates cell polarity and extracellular matrix remodelling. The convergence of mechanistic studies and therapeutic targeting efforts underscores PTK7 as both a biomarker and a promising target for novel anticancer strategies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

PTK7 Signaling in Cancer Development and Progression publication trend

The graph below shows the total number of articles in ptk7 signaling in cancer development and progression across all publications each year (not limited to Nature Index journals).

Technical terms

PTK7: A catalytically inactive receptor tyrosine pseudokinase that modulates signalling by interacting with active kinases and co-receptors.

Pseudokinase: A kinase-like protein lacking key residues for catalytic activity but retaining scaffolding or regulatory functions.

Receptor tyrosine kinase (RTK): A membrane receptor that, upon ligand binding, dimerises and phosphorylates tyrosine residues to initiate intracellular signalling.

Wnt signalling: A conserved pathway controlling cell fate and proliferation, subdivided into canonical (β-catenin-dependent) and non-canonical branches.

Antibody–drug conjugate: A targeted therapy combining a monoclonal antibody specific for a cell-surface antigen with a cytotoxic payload.

CAR-T cell therapy: A form of adoptive cell therapy in which patient T cells are engineered to express a chimeric antigen receptor targeting a tumour antigen.

References

1. FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development. Cell Death & Disease (2024).
2. Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer. Oncogene (2024).
3. Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling. International Journal of Molecular Sciences (2023).
4. The Cytosolic Domain of Protein-tyrosine Kinase 7 (PTK7), Generated from Sequential Cleavage by a Disintegrin and Metalloprotease 17 (ADAM17) and γ-Secretase, Enhances Cell Proliferation and Migration in Colon Cancer Cells*. Journal of Biological Chemistry (2012).